# A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF

> **NCT01326962** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 28 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** tocilizumab [RoActemra/Actemra]

## Key facts

- **NCT ID:** NCT01326962
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11-30
- **Primary completion:** 2013-05-12
- **Final completion:** 2013-05-12
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2017-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01326962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01326962, "A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01326962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*